US › Healthcare

Agenus Inc (AGEN)

US · Healthcare · Biotechnology

$6.04-9.58%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$34.5M

Revenue YoY

+34.4%

Net profit

$-550,000

EPS

$-0.01

EPS estimate

$0.05

Net margin

-1.6%

EPS came in at -0.01 against a street estimate of 0.05 — a miss of 120.0%.

Key statistics

Market cap

$313.9M

P/E

2.7

Forward P/E

3.7

P/B

218.61

Book value

$-4.67

EPS (TTM)

$2.53

52-week high

$10.31

52-week low

$2.71

50-day MA

$7.83

200-day MA

$4.72

Beta

1.32

Analyst view

Analysts rate Agenus Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $26.33.

Shareholding

Insiders

6.27%

Institutions

46.40%

Largest institutional holders

Fund	Stake
BlackRock Inc	5.68%
Vanguard Capital Management, LLC	3.71%
Vanguard Portfolio Management, LLC	3.16%
Siren, L.L.C.	2.36%
Geode Capital Management, LLC	2.29%
Mackenzie Investments	1.58%
The Goldman Sachs Group Inc	0.99%
Marshall Wace Asset Management Ltd	0.97%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Agenus Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.